Last reviewed · How we verify
NCT04631861
Physical Activity and the Risk of COVID-19 Infection and Mortality
trial in Covid19 in 132,069 participants. Completed in 31 July 2020.
31 July 2020
Quick facts
| Lead sponsor | Wonju Severance Christian Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 132,069 |
| Start date | 1 January 2014 |
| Primary completion | 31 July 2020 |
| Estimated completion | 31 July 2020 |
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Wonju Severance Christian Hospital
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no cure for COVID-19, except for supportive treatments. Quarantine for a defined period is the best option to reduce the spread of COVID-19. Physical activity has been shown to reduce the risk of serious community-acquired infections. However, it remains unanswered is whether physical activity has protective effects against SARS-CoV-2 infection and COVID-19 related mortality. This study aimed to examine the association of PA with the morbidity and mortality of COVID-19 infection in the entire South Korean population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04631861
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Wonju Severance Christian Hospital trials
Trials by the same sponsor.
- NCT07012499 — QOL and Mental Health Using APD With Remote Monitoring System · NA · enrolling by invitation
- NCT07146178 — Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS · NA · not yet recruiting
- NCT06675396 — Pharmacogenomics of Mood Disorder in Chronic Kidney Disease Patients · not yet recruiting
- NCT06540430 — Digital Based Home Care Service for Ostomy Patients · NA · not yet recruiting
- NCT07017088 — Efficacy of Leuconostoc Mesenteroides · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04631861 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wonju Severance Christian Hospital
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04631861.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing